Navigation Links
Arena Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference
Date:12/6/2012

SAN DIEGO, Dec. 6, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Oppenheimer 23rd Annual Healthcare Conference on Wednesday, December 12, 2012, at 9:25 a.m. Eastern Time (6:25 a.m. Pacific Time) at The Waldorf Astoria in New York City.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. BELVIQ® (lorcaserin HCl), Arena's internally discovered drug, was approved by the US Food and Drug Administration in June 2012, and is under review for regulatory approval in additional jurisdictions. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information about Arena, please visit www.arenapharm.com.

Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statem
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals Announces First Quarter 2012 Financial Results and Recent Developments
2. Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
3. Arena Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
4. Aperture Health, Inc., Targeting the Strong Growth in the Long Term Disease Management arena
5. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
6. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
7. Arena Pharmaceuticals Files Marketing Authorization Application in Switzerland for Lorcaserin as a Treatment for Weight Control
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
9. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
10. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
11. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (NYSE: RMD ), a pioneer and innovator in ... sleep apnea solutions specifically for women, is launching a new ... night,s sleep. The Better Sleep For Women ... just part of living a busy life. It will encourage ... health, essential to not only living an active lifestyle but ...
(Date:10/1/2014)... , Oct. 1, 2014  Varian Medical Systems ... will report results for the fourth quarter of fiscal ... Wednesday, October 22, 2014.  The news release will be ... at 2:00 p.m. PT.  The news release and a ... on the company website at: www.varian.com/investor .  To ...
(Date:10/1/2014)... , Oct. 1, 2014   Royal ... PHIA) today announced its eCareCoordinator and eCareCompanion telehealth ... Food and Drug Administration (FDA). A part of ... programs , eCareCoordinator and eCareCompanion are focused on ... first clinical applications to be available through the ...
Breaking Medicine Technology:ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4
... Jan. 11, 2011 Reportlinker.com announces that a ... catalogue: Novo Nordisk A/S: PharmaVitae ... Introduction This ... Novo Nordisk in the prescription pharmaceutical sector. The ...
... 11, 2011 Reportlinker.com announces that ... available in its catalogue: ... New pricing rules set to negatively ... internationally http://www.reportlinker.com/p0360217/Germany-Pharmaceutical-Market-Overview-–-New-pricing-rules-set-to-negatively-impact-drug-sales-both-domestically-and-internationally.html ...
Cached Medicine Technology:Reportlinker Adds Novo Nordisk A/S: PharmaVitae Profile 2Reportlinker Adds Germany Pharmaceutical Market Overview - New pricing rules set to negatively impact drug sales both domestically and internationally 2
(Date:10/1/2014)... beta-amyloid is strongly associated with Alzheimer,s disease; however, researchers ... is the causal agent of the onset and development ... is that beta-amyloid is not harmful when found in ... it self-assembles to form the so-called amyloid fibrils , ... alone, but with multiple ones because each aggregate of ...
(Date:10/1/2014)... by the Engineering and Physical Sciences Research Council ... UK,s vital industrial control systems which run, for ... and the rail network. , The research ... or malware infiltrating the systems behind our critical ... Trustworthy Industrial Control Systems (RITICS), based at Imperial ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog post ... , Senior citizens can qualify for affordable term ... seniors who are over 50 years old. Some term ... medical examination. , Term life insurance with a simplified ... qualify. Having life insurance during retirement is important for ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining ... smokers. , Smoking will always have a negative impact ... best method to find affordable coverage. Insurance brokerage websites ... , Whole life insurance premiums will be fixed ... coverage is permanent, the initial rates are very ...
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2
... new study shows men with prostate cancer who receive a ... reduce // the risk of recurrence after surgery may be ... showed men treated with androgen deprivation therapy (ADT) after prostate ... most common among women. Men who are older, smoke, or ...
... with the oral drug bosentan (Tracleer) has led to ... hypertension ( PAH) // . ,PAH is usually ... believed to cause the overproduction of endothelin, which increases ... This chronic obstruction leads to PAH, a condition that ...
... intense course of radiation after a lumpectomy may be ... on findings of a recent study. Standard treatment for ... weeks of radiation daily after undergoing surgery , however ... treatment is a major inconvenience leading them to choose ...
... a urinary tract infection can increase your chances of having ... few days, say researchers based on findings of a recent ... anytime we have an infection, to atherosclerosis, or clogging of ... of infections, some have speculated they, too, could aggravate the ...
... the existing drugs on the market are losing their ... bacteria hence researchers feel that the ocean is a ... ,More than 1 million microorganisms fill every milliliter of ... for some of our deadliest diseases. Many marine organisms ...
... J. Rutter, a well known scientist and accomplished businessman ... patent applications,has announced intention to set up a high ... of "Hemogenomics", which will be a marketing, selling and ... the sidelines of the BioAsia 2004 conference Bangalore on ...
Cached Medicine News:
Based on the clinically proven ACS MULTI-LINK Stent, ULTRA is a coronary stent system specifically designed for use in larger vessels. This innovative system utilizes a unique stent pattern to give y...
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Now available in 2.75-mm diameters, the S660 small vessel coronary stent expands your treatment options for accurate sizing and precision stenting....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
Medicine Products: